Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial

BACKGROUND: Treatment options for pretreated triple-negative breast cancer (TNBC) are limited. This study aimed to evaluate the efficacy and safety of apatinib, an antiangiogenic agent, in combination of etoposide for pretreated patients with advanced TNBC. METHODS: In this single-arm phase II trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Mengru, Lu, Hailing, Yan, Shi, Pang, Hui, Sun, Lichun, Li, Chunhong, Chen, Xuesong, Liu, Wei, Hu, Jing, Huang, Jian, Xing, Ying, Zhang, Ningzhi, Chen, Yingqi, He, Ting, Zhao, Danni, Sun, Yuanyuan, Zhao, Lin, Liu, Xiaomeng, Cai, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197030/
https://www.ncbi.nlm.nih.gov/pubmed/37208633
http://dx.doi.org/10.1186/s12885-023-10768-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197030/
https://www.ncbi.nlm.nih.gov/pubmed/37208633
http://dx.doi.org/10.1186/s12885-023-10768-8

Ejemplares similares